<DOC>
	<DOC>NCT01178086</DOC>
	<brief_summary>This observational study will assess the therapeutic efficiency, the treatment schedules and handling procedures, and the safety profile of MabThera/Rituxan (rituximab) in routine care in patients with chronic lymphocytic leukemia. Data from patients will be collected for a total of 24 months.</brief_summary>
	<brief_title>An Observational Study on MabThera/Rituxan (Rituximab) in Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Chronic lymphocytic leukemia requiring treatment Patients receive a chemotherapy in combination with MabThera/Rituxan (decision taken by doctor prior to and independent from inclusion in this noninterventional study) Comorbidities according to CIRS score &gt;6 and/or creatinine clearance &lt;70 ml/min Unable or unwilling to give informed consent Contraindication to MabThera/Rituxan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>